Research
Working towards a cure with some of Australia’s leading brain cancer specialists
Ahead of the curve
Identifying the changes that occur when gliomas recur and progress gives us a much more comprehensive picture of the biology of the tumours. We are currently using this knowledge to develop strategies to prevent gliomas from recurring and progressing in patients.
Biomarkers, or molecules which are characteristic of certain conditions, are extremely important for managing the welfare of glioma patients. Such biomarkers can be used to identify other morbidities where specific medications, such as anti-clotting agents, could be life-saving. We are currently investigating whether specific molecular features can predict which glioma patient would benefit from anti-clotting agents.
Preclinical Research
Our work
In collaboration with TBCG and the Bill Walsh Translational Cancer Research Lab, our pre-clinical research team have one major goal, to improve treatments and patient outcomes for those suffering from glioma.
Under this major goal, we have 3 major research themes:
- Studying the molecular changes associated with tumour recurrence and progression in both IDH-mutated gliomas and high grade glioma
- Identifying molecular biomarkers associated with co-morbidities in glioma patients
- Identify new treatments for glioma patients
Our pre-clinical research team currently consists of Dr Helen Wheeler, Post-doctoral fellow Dr Amanda Hudson, Medical Oncologist Dr Adrian Lee, Dr Alex Yuile and Dr Julius Kim.
If you would like to know more about our research or would like to become involved, please contact us.
Clinical research
Brain Cancer Databank
The comprehensive DataBank will comprise data from three linked projects under TBCG. Conceptually once established every patient will be entered into the TBCG Brain Cancer DataBank through a linked pathway in which their initial brain tumour specimen is stored, alongside their actual brain cancer images and their information data. A scientist asking a question can then access the actual brain tumour specimen, and see how that influences the MRI appearance and treatment outcomes. It will be a powerful future resource for the Brain Cancer community.
Our latest initiative
The Imaging Lab
This is new imaging databank under development paralleling the principles of the Brain Tumour BioBank and Laboratory gathering the actual images from patients for future study and assessment.
It will be the only Imaging Laboratory in Australia and be a great resource for local and international researchers.
Publications
- Chan J, Jayamanne D, Wheeler H, Khasraw M, Wong M, Kastelan M, Guo L, Back M. The role of large volume re-irradiation with Bevacizumab in chemorefractory highgrade glioma. Clin Transl Radiat Oncol. 2020 Mar 9;22:33-39. doi: 10.1016/j.ctro.2020.03.005.eCollection 2020 May.
- Anderson KJ, Tan AC, Parkinson J, Back M, Kastelan M, Newey A, Brewer J,Wheeler H, Hudson AL, Amin SB, Johnson KC, Barthel FP, Verhaak RGW, Khasraw M. Molecular and clonal evolution in recurrent metastatic gliosarcoma. Cold Spring Harb Mol Case Stud. 2020 Feb 3;6(1):a004671. doi:10.1101/mcs.a004671. Print 2020 Feb.
- Back MF, Jayamanne D, Back E, Kastelan M, Khasraw M, Wong M, Brown C, Wheeler H. Reflecting on survivorship outcomes to aid initial decision making in patients treated for IDH-mutated anaplastic glioma. Cancer. 2019 Oct 1;125(19):3457-3466. doi: 10.1002/cncr.32352. Epub 2019 Jun 28.
- Cuncannon M, Wong M, Jayamanne D, Guo L, Cove N, Wheeler H, Back M. Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma. BMC Cancer. 2019 May 14;19(1):445. doi: 10.1186/s12885-019-5678-1.
- Or M, Jayamanne D, Guo L, Stevens M, Parkinson J, Cook R, Little N, Back M. Focal radiation therapy for limited brain metastases is associated with high rates of local control and low subsequent whole brain radiation therapy. ANZ J Surg. 2019 Apr;89(4):418-422. doi: 10.1111/ans.15040. Epub 2019 Mar 5.
- Dirven L, Reijneveld JC, Taphoorn MJB, Coens C, El-Badawy SA, Tzuk-Shina T, Bravo-Marques J, Back M, Stalpers LJA, Stupp R, Baumert BG, Seidel C. Impact of Radiation Target Volume on Health-Related Quality of Life in Patients With Low-Grade Glioma in the 2-Year Period Post Treatment: A Secondary Analysis of the EORTC 22033-26033. Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):90-100. doi: 10.1016/j.ijrobp.2019.01.003. Epub 2019 Feb 2.
- Ibbett I, Schembri G, Cook R, Parkinson J. Role of 18F-fluoro-ethyl-tyrosine Positron Emission Tomography in Investigation and Management of Suspected Gliomas. World Neurosurg. 2019 Jan;121:e712-e715. doi: 10.1016/j.wneu.2018.09.194. Epub 2018 Oct 6.
- Back M, Jayamanne DT, Brazier D, Newey A, Bailey D, Schembri GP, Hsiao E, Khasraw M, Wong M, Kastelan M, Guo L, Clarke S, Wheeler H. Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management. J Med Imaging Radiat Oncol. 2019 Apr;63(2):272-280. doi: 10.1111/1754-9485.12850. Epub 2019 Jan 24.
- Back M, Jayamanne D, Brazier D, Bailey D, Hsiao E, Guo L, Wheeler H. Tumour volume reduction following PET guided intensity modulated radiation therapy and temozolomide in IDH mutated anaplastic glioma. J Clin Neurosci. 2019 Jan;59:68-74. doi: 10.1016/j.jocn.2018.11.005. Epub 2018 Nov 14.
- Chan DL, Hsiao E, Schembri G, Bailey DL, Roach PJ, Lee A, Jayamanne D, Ghasemzadeh M, Hayes A, Cook R, Parkinson J, Drummond JP, Ibbett I, Wheeler HR, Back M. FET PET in the evaluation of indeterminate brain lesions on MRI: Differentiating glioma from other non-neoplastic causes – A pilot study. J Clin Neurosci. 2018 Dec;58:130-135. doi: 10.1016/j.jocn.2018.09.009. Epub 2018 Sep 19.
- Back M, Jayamanne D, Cove N, Wheeler H, Khasraw M, Guo L, Back J, Wong M. Optimising Outcomes for Glioblastoma through Subspecialisation in a Regional Cancer Centre. Brain Sci. 2018 Oct 15;8(10). pii: E186. doi: 10.3390/brainsci8100186.
- McKelvey KJ, Hudson AL, Back M, Eade T, Diakos CI.
Mamm Genome. Radiation, inflammation and the immune response in cancer. 2018 Dec;29(11-12):843-865. doi: 10.1007/s00335-018-9777-0. Epub 2018 Sep 3. Review. - Jayamanne D, Wheeler H, Brazier D, Newey A, Kastelan M, Guo L, Back M. Predicting patterns of failure in temporal lobe GBMs: possible implications on radiotherapy treatment portals. Radiat Oncol. 2018 Jul 20;13(1):133. doi: 10.1186/s13014-018-1078-y.
- Back M, Rodriguez M, Jayamanne D, Khasraw M, Lee A, Wheeler H. Understanding the Revised Fourth Edition of the World Health Organization Classification of Tumours of the Central Nervous System (2016) for Clinical Decision-making: A Guide for Oncologists Managing Patients with Glioma. Clin Oncol (R Coll Radiol). 2018 Sep;30(9):556-562. doi: 10.1016/j.clon.2018.06.005. Epub 2018 Jul 3.
- Hayes AR, Jayamanne D, Hsiao E, Schembri GP, Bailey DL, Roach PJ, Khasraw M, Newey A, Wheeler HR, Back M. Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma. Pract Radiat Oncol. 2018 Jul – Aug;8(4):230-238. doi: 10.1016/j.prro.2018.01.006. Epub 2018 Jan 31.
- Jayamanne D, Wheeler H, Cook R, Teo C, Brazier D, Schembri G, Kastelan M, Guo L, Back MF. Survival improvements with adjuvant therapy in patients with glioblastoma. ANZ J Surg. 2018 Mar;88(3):196-201. doi: 10.1111/ans.14153. Epub 2017 Sep 18.
- Jaymanne DT, Kaushal S, Chan D, Schembri G, Brazier D, Bailey D, Wheeler H, Back M. Utilizing 18F-fluoroethyl-l-tyrosine positron emission tomography in high grade glioma for radiation treatment planning in patients with contraindications to MRI.
J Med Imaging Radiat Oncol. 2018 Feb;62(1):122-127. doi: 10.1111/1754-9485.12676. Epub 2017 Oct 5. - McKelvey, K.J., Hudson, A.L., Back, M., Eade, T. and Diakos, C. Radiation and inflammation/immune response in cancer. Mammalian Genome, invited review, 2018, 29 (11-12), 843-865.
- Hudson, A.L., Parker, N.R., Khong, P., Parkinson, J.F., Ikin, R.J., Zhu, Y., Wheeler, HR and Howell, V.M. Glioblastoma Recurrence Correlates with Increased APE1 and Polarisation Towards an Immuno-Suppressive Microenvironment. Frontiers in Oncology, 2018, 8:314.
- Cho, A., McKelvey, K.J., Lee, A. and Hudson, A.L. The intertwined fates of inflammation and coagulation in glioma. Mammalian Genome, invited review, 2018, 29 (11-12), 806-816.
- Jayamanne D, Wheeler H, Cook R, Teo C, Brazier D, Schembri G, Kastelan M, Guo L, Back MF. Survival improvements with adjuvant therapy in patients with glioblastoma. ANZ J Surg. 2018 Mar;88(3):196-201. doi: 10.1111/ans.14153. Epub 2017 Sep 18.
- Jaymanne DT, Kaushal S, Chan D, Schembri G, Brazier D, Bailey D, Wheeler H, Back M. Utilizing 18F-fluoroethyl-l-tyrosine positron emission tomography in high grade glioma for radiation treatment planning in patients with contraindications to MRI.
J Med Imaging Radiat Oncol. 2018 Feb;62(1):122-127. doi: 10.1111/1754-9485.12676. Epub 2017 Oct 5. - McKelvey, K.J., Hudson, A.L., Back, M., Eade, T. and Diakos, C. Radiation and inflammation/immune response in cancer. Mammalian Genome, invited review, 2018, 29 (11-12), 843-865.
- Hudson, A.L., Parker, N.R., Khong, P., Parkinson, J.F., Ikin, R.J., Zhu, Y., Wheeler, HR and Howell, V.M. Glioblastoma Recurrence Correlates with Increased APE1 and Polarisation Towards an Immuno-Suppressive Microenvironment. Frontiers in Oncology, 2018, 8:314.
- Cho, A., McKelvey, K.J., Lee, A. and Hudson, A.L. The intertwined fates of inflammation and coagulation in glioma. Mammalian Genome, invited review, 2018, 29 (11-12), 806-816.
- Perry J, Laperriere N, O’Callaghan C, Brandes A, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross G, Roa W, Osoba D, Rossiter J, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Golfinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert B, Wick W, Ding K, Mason W. Short-Course Radiation with Temozolomide in Elderly Glioblastoma Patients. N Engl J Med. 2017 Mar 16; 376(11):1027-1037.
- Back M, LeMottee M; Crasta C; Bailey D; Wheeler H; Guo L; Eade T. Reducing radiation dose to normal brain through a risk adapted dose reduction protocol for patients with favourable subtype anaplastic glioma.
Radiat Oncol. 2017 Mar 2; 12(1):46. - French H, Somasundaram A, Biggs M, Parkinson J, Allan R, Ball J, Little N. Idiopathic intradural dorsal thoracic arachnoid cysts: A case series and review of the literature. J Clin Neurosci. 2017 Mar 17.
- Harris G, Jayamanne D, Wheeler H, Gzell C, Kastelan M, Schembri G, Brazier D, Cook R, Parkinson J, Khasraw M, Louw S, and Back M. Survival outcome of elderly patients with Glioblastoma Multiforme in their seventy-fifth year or older treated with adjuvant therapy.
Accepted International Journal of Radiation Oncology Biology Physics Mar 2017
- Gzell C, Back M, Wheeler H, Bailey D, Foote M. Radiotherapy in Glioblastoma: the Past, the Present and the Future. Clin Oncol (R Coll Radiol). 2016 Oct 13.
- Reijneveld JC, Taphoorn MJ, Coens C, Bromberg JE, Mason WP,Hoang-Xuan K, Ryan G, Hassel MB, Enting RH, Brandes AA, Wick A, Chinot O, Reni M, Kantor G, Thiessen B, Klein M, Verger E, Borchers C, Hau P, Back M, Smits A, Golfinopoulos V, Gorlia T, Bottomley A, Stupp R, Baumert BG. Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): A randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016 Sep 26. 68.
- Brandes AA, Carpentier AF, Kesari S, Sepulveda-Sanchez JM, Wheeler HR, Chinot O, Cher L, Steinbach JP, Capper D, Specenier P, Rodon J, Cleverly A, Smith C, Gueorguieva I, Miles C, Guba SC, Desaiah D, Lahn MM, Wick W.A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. Neuro Oncol. 2016 Aug; 18(8):1146-56.
- Ramaswamy V, Hielscher T, Mack SC, Lassaletta A, Lin T, Pajtler KW, Jones DT, Luu B, Cavalli FM, Aldape K, Remke M, Mynarek M, Rutkowski S, Gururangan S, McLendon RE, Lipp ES, Dunham C, Hukin J, Eisenstat DD, Fulton D, van Landeghem FK, Santi M, van Veelen ML, Van Meir EG, Osuka S, Fan X, Muraszko KM, Tirapelli DP, Oba-Shinjo SM, Marie SK, Carlotti CG, Lee JY, Rao AA, Giannini C, Faria CC, Nunes S, Mora J, Hamilton RL, Hauser P, Jabado N, Petrecca K, Jung S, Massimi L, Zollo M, Cinalli G, Bognár L, Klekner A, Hortobágyi T, Leary S, Ermoian RP, Olson JM, Leonard JR, Gardner C, Grajkowska WA, Chambless LB, Cain J, Eberhart CG, Ahsan S, Massimino M, Giangaspero F, Buttarelli FR, Packer RJ, Emery L, Yong WH, Soto H, Liau LM, Everson R, Grossbach A, Shalaby T, Grotzer M, Karajannis MA, Zagzag D, Wheeler H, von Hoff K, Alonso MM, Tuñon T, Schüller U, Zitterbart K, Sterba J, Chan JA, Guzman M, Elbabaa SK, Colman H, Dhall G, Fisher PG, Fouladi M, Gajjar A, Goldman S, Hwang E, Kool M, Ladha H, Vera-Bolanos E, Wani K, Lieberman F, Mikkelsen T, Omuro AM, Pollack IF, Prados M, Robins HI, Soffietti R, Wu J, Metellus P, Tabori U, Bartels U, Bouffet E, Hawkins CE, Rutka JT, Dirks P, Pfister SM, Merchant TE, Gilbert MR, Armstrong TS, Korshunov A, Ellison DW, Taylor MD.et al. Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. J Clin Oncol. 2016 Jul 20; 34(21):2468-77.
- Gzell C, Wheeler H, Huang D, Gaur P, Chen J, Kastelan M, Back M. Proliferation Index Predicts Survival after Second Craniotomy within 6 Months of Adjuvant Radiotherapy for High-grade Glioma. Clin Oncol (R Coll Radiol). 2016 Mar; 28(3):215-22.
- Khasraw M, Lee A, McCowatt S, Kerestes Z, Buyse ME, Back M, Kichenadasse G, Ackland S, Wheeler H. Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial. J Neurooncol. 2016 Mar 2.
- Harris G, Cook R, Teo C, Jayamanne D, Guo L and Back M. Cerebral Oligometastases: Low rate of subsequent Whole Brain Radiotherapy following Local Therapy. J Brain Tumours Neurooncol 1: 3 2016.
- Parker NR, Hudson AL, Khong P, Parkinson JF, Dwight T, Ikin RJ, Zhu Y, Cheng ZJ, Vafaee F, Chen J, Wheeler HR, Howell VM.Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma. Sci Rep. 2016 Mar 4;6:22477
- Gzell CE, Wheeler HR, McCloud P, Kastelan M, Back M. Small increases in enhancement on MRI may predict survival post radiotherapy in patients with glioblastoma. J Neurooncol. 2016 Feb 15.
- Morrissy AS, Garzia L, Shih DJ, Zuyderduyn S, Huang X, Skowron P, Remke M, Cavalli FM, Ramaswamy V, Lindsay PE, Jelveh S, Donovan LK, Wang X, Luu B, Zayne K, Li Y, Mayoh C, Thiessen N, Mercier E, Mungall KL, Ma Y, Tse K, Zeng T, Shumansky K, Roth AJ, Shah S, Farooq H, Kijima N, Holgado BL, Lee JJ, Matan-Lithwick S, Liu J, Mack SC, Manno A, Michealraj KA, Nor C, Peacock J, Qin L, Reimand J, Rolider A, Thompson YY, Wu X, Pugh T, Ally A, Bilenky M, Butterfield YS, Carlsen R, Cheng Y, Chuah E, Corbett RD, Dhalla N, He A, Lee D, Li HI, Long W, Mayo M, Plettner P, Qian JQ, Schein JE, Tam A, Wong T, Birol I, Zhao Y, Faria CC, Pimentel J, Nunes S, Shalaby T, Grotzer M, Pollack IF, Hamilton RL, Li XN, Bendel AE, Fults DW, Walter AW, Kumabe T, Tominaga T, Collins VP, Cho YJ, Hoffman C, Lyden D, Wisoff JH, Garvin JH Jr, Stearns DS, Massimi L, Schüller U, Sterba J, Zitterbart K, Puget S, Ayrault O, Dunn SE, Tirapelli DP, Carlotti CG, Wheeler H, Hallahan AR, Ingram W, MacDonald TJ, Olson JJ, Van Meir EG, Lee JY, Wang KC, Kim SK, Cho BK, Pietsch T, Fleischhack G, Tippelt S, Ra YS, Bailey S, Lindsey JC, Clifford SC, Eberhart CG, Cooper MK, Packer RJ, Massimino M, Garre ML, Bartels U, Tabori U, Hawkins CE, Dirks P, Bouffet E, Rutka JT, Wechsler-Reya RJ, Weiss WA, Collier LS, Dupuy AJ, Korshunov A, Jones DT, Kool M, Northcott PA, Pfister SM, Largaespada DA, Mungall AJ, Moore RA, Jabado N, Bader GD, Jones SJ, Malkin D, Marra MA, Taylor MD. Divergent clonal selection dominates medulloblastoma at recurrence. Nature. 2016 Jan 21; 529(7586):351-7.
- Back M, Gzell CE, Kastelan M, Guo L, Wheeler HR. Large volume re-irradiation with bevacizumab is a feasible salvage option for patients with refractory high-grade glioma. Neurooncol Pract. 2015 Mar; 2(1):48-53.
- Field KM, Simes J, Nowak AK, Cher L, Wheeler H, Hovey EJ, Brown CS, Barnes EH, Sawkins K, Livingstone A, Freilich R, Phal PM, Fitt G; CABARET/COGNO investigators., Rosenthal MA.Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma. Neuro Oncol. 2015 Nov; 17(11):1504-13.
- Bailey A, Trad W, Kastelan M, Lamont S. Australian experience of neuro-oncology care coordination: a conversation. Clin J Oncol Nurs. 2015 Oct; 19(5):610-4.
- Trad W, Koh ES, Daher M, Bailey A, Kastelan M, Legge D, Fleet M, Simpson GK, Hovey E. Screening for Psychological Distress in Adult Primary Brain Tumor Patients and Caregivers: Considerations for Cancer Care Coordination. Front Oncol. 2015 Sep 22; 5:203.
- Tsang VH1, Dwight T, Benn DE, Meyer-Rochow GY, Gill AJ, Sywak M, Sidhu S, Veivers D, Sue CM, Robinson BG, Clifton-Bligh RJ, Parker NR. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours. Endocr Relat Cancer. 2014 May 6; 21(3):415-26.
- Halkett GK, Lobb EA, Rogers MM, Shaw T, Long AP, Wheeler HR, Nowak AK Predictors of distress and poorer quality of life in High Grade Glioma patients. Patient Educ Couns. 2015 Apr;98(4):525-32
- Back M1, Gzell CE1, Kastelan M1, Guo L1, Wheeler HR1.Large volume re-irradiation with bevacizumab is a feasible salvage option for patients with refractory high-grade glioma. Neurooncol Pract. 2015 Mar; 2(1):48-53.
- Parker NR, Khong P, Parkinson JF, Howell VM, Wheeler HR Molecular heterogeneity in glioblastoma: potential clinical implications. Front Oncol. 2015 Mar 3;5:55
- Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N.Antiangiogenic therapy for high-grade glioma. Cochrane Database Syst Rev. 2014 Sep 22 ;(9):CD008218.
- Gzell C, Wheeler H, Guo L, Kastelan M, Back M. Elderly patients aged 65-75 years with glioblastoma multiforme may benefit from long course radiation therapy with temozolomide. J Neurooncol. 2014 Aug; 119(1):187-96.
- Tabone T, Abuhusain HJ, Nowak AK; Australian Genomics and Clinical Outcome of Glioma (AGOG) Network. Erber WN, McDonald KL.Multigene profiling to identify alternative treatment options for glioblastoma: a pilot study. J Clin Pathol. 2014 Jul; 67(7):550-5.
- Back M, Back E, Wheeler H. Cognitive Deficits in Primary Brain Tumours: A Framework for Management and Rehabilitation. Journal of Cancer Therapy. 2014 Jan; 5:1
- Back M, Clifford S, Wheeler H, Guo L, Eade T. Dosimetric improvements utilizing Intensity Modulated Radiation Therapy for Patients with Glioblastoma Multiforme. Journal of Cancer Therapy. 2013 Dec; 4:11A.
- Gzell C, Wheeler H, Guo L, Kastelan M, Back M. Employment following chemoradiotherapy in glioblastoma: a prospective case series. J Cancer Surviv. 2013 Nov 9.
- Gupta R, Flanagan S, Li CC, Lee M, Shivalingham B, Maleki S, Wheeler HR, Buckland ME. Expanding the spectrum of IDH1 mutations in gliomas. Mod Pathol. 2013 May; 26(5):619-25.
- Parker NR1, Correia N2, Crossley B2, Buckland ME3, Howell VM1, Wheeler HR4. Correlation of MicroRNA 132 Up-regulation with an Unfavorable Clinical Outcome in Patients with Primary Glioblastoma Multiforme Treated with Radiotherapy plus Concomitant and Adjuvant Temozolomide Chemotherapy. Transl Oncol. 2013 Dec 1; 6(6):742-8.
- McDonald KL, Rapkins RW, Olivier J, Zhao L, Nozue K, Lu D, Tiwari S, Kuroiwa-Trzmielina J, Brewer J, Wheeler HR, Hitchins MP. The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients. Eur J Cancer. 2013 Jan; 49(2):360-8.
- Wheeler H, Black J, Webb S, Shen H.Dehiscence of corticosteroid-induced abdominal striae in a 14-year-old boy treated with bevacizumab for recurrent glioblastoma. J Child Neurol. 2012 Jul; 27(7):927-9.
- Fowler A, Thomson D, Giles K, Maleki S, Mreich E, Wheeler H, Leedman P, Biggs M, Cook R, Little N, Robinson B, McDonald K. miR-124a is frequently down-regulated in glioblastoma and is involved in migration and invasion. Eur J Cancer. 2011 Apr;47(6):953-63.
- Gonzalvo A, Fowler A, Cook RJ, Little NS, Wheeler H, McDonald KL, Biggs MT. Schwannomatosis, sporadic schwannomatosis, and familial schwannomatosis: a surgical series with long-term follow-up. J Neurosurg. 2011 Mar; 114(3):756-62.
- Parkinson JF, Afaghi V, Payne CA, Buckland ME, Brewer JM, Biggs MT, Little NS, Wheeler HR, Cook RJ, McDonald KL. The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years’ experience at a single centre. J Clin Neurosci. 2011 Mar; 18(3):329-33.
- Dobes M, Shadbolt B, Khurana VG, Jain S, Smith SF, Smee R, Dexter M, Cook R. A multicenter study of primary brain tumor incidence in Australia (2000-2008).Neuro Oncol. 2011 Jul; 13(7):783-90.
- Gonzalvo A, McKenzie C, Harris M, Biggs M. Primary non-Hodgkin’s lymphoma of the radial nerve: case report. Neurosurgery. 2010 Sep;67(3):E872-3;
- Matar E, Cook R, Fowler A, Biggs M, Little N, Wheeler H, Robinson B, McDonald K. Post-contrast enhancement status as a clinical indicator of prognosis in Patients with anaplastic astrocytoma. J Clin Neurosci. 2010 Aug; 17(8):993-6.
- McDonald KL, McDonnell J, Muntoni A, Henson JD, Hegi ME, von Deimling A, Wheeler HR, Cook RJ, Biggs MT, Little NS, Robinson BG, Reddel RR, Royds JA. “The presence of Alternative Lengthening of Telomere (ALT) mechanism in Patients with glioblastoma multiforme identifies a less aggressive tumour Type and longer survival. J Neuropathol Exp Neurol. 2010 Jul; 69(7):729-36.
- Payne CA, Maleki S, Messina M, O’Sullivan MG, Stone G, Hall NR, Parkinson JF, Wheeler HR, Cook RJ, Biggs MT, Little NS, Teo C, Robinson BG, McDonald KL.Loss of prostaglandin D2 synthase: a key molecular event in the transition of a low-grade astrocytoma to an anaplastic astrocytoma. Mol Cancer Ther. 2008 Oct; 7(10):3420-8.
- Fowler A, Cook R, Biggs M, Little N, Assaad N, McDonald K. Survival of patients following neurosurgical treatment of colorectal adenocarcinoma metastasis in the Northern Sydney-Central Coast area. J Clin Neurosci. 2008 Sep; 15(9):998-1004.
- Parkinson JF, Wheeler HR, Clarkson A, McKenzie CA, Biggs MT, Little NS, Cook RJ, Messina M, Robinson BG, McDonald KL. Variation of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma.J Neurooncol. 2008 Mar; 87(1):71-8.
- Parkinson JF, Wheeler HT, McDonald KL. Contributions of DNA repair mechanisms to determining chemotherapy response in high-grade glioma. J Clin Neurosci. 2008 Jan; 15(1):1-8.
- McDonald KL, O’Sullivan MG, Parkinson JF, Shaw JM, Payne CA, Brewer JM, Young L, Reader DJ, Wheeler HT, Cook RJ, Biggs MT, Little NS, Teo C, Stone G, Robinson BG. IQGAP1 and IGFBP2: valuable biomarkers for determining prognosis in glioma patients. J Neuropathol Exp Neurol. 2007 May; 66(5):405-17.
- Smith SF, Simpson JM, Brewer JA, Sekhon LH, Biggs MT, Cook RJ, Little NS. “The Presence of Necrosis and/or Microvascular Proliferation Does Not Influence Survival of Patients with Anaplastic Oligodendroglial Tumours: Review of 98 Patients” J Neurooncol. 2006 Oct; 80(1):75-82.
- Yuile P, Dent O, Cook R, Biggs M, Little N. Survival of Glioblastoma patients related to presenting symptoms, brain site and treatment variables. J Clin Neurosci. 2006 Aug; 13(7):747-51.
- Smith SF, Simpson JM, Sekhon LH. What progress has been made in surgical management of patients with astrocytoma and oligodendroglioma in Australia over the last two decades? J Clin Neurosci. 2005 Nov;12(8):915-20
- Smith SF, Biggs MT, Sekhon LH. Risk factors and prophylaxis for deep venous thrombosis in neurosurgery Surg Technol Int. 2005; 14:69-76.
- A quarter of a century of neurosurgery: the value of a relational database to document trends in neurosurgical practice of a tertiary referral hospital. Smith SF, Simpson JM, Sekhon LH. J Clin Neurosci. 2004 Jan; 11(1):31-6.
- Marx GM, Pavlakis N, McCowatt S, Boyle FM, Levi JA, Bell DR, Cook R, Biggs M, Little N, Wheeler HR. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme.J Neurooncol. 2001 Aug; 54(1):31-8.
- Biggs MT. Posterior subscapular approach for specific brachial plexus lesions. J Clin Neurosci. 2001 Jul; 8(4):340-2.
Our partners
